| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Neurology testing overview
The rapid expansion of neurology testing has resulted in the discovery of increasing numbers of clinically relevant biomarkers. Mayo Clinic Laboratories collaborates closely with the clinical practice to develop and offer advanced testing — much of which is unavailable anywhere else — to address the most difficult questions.
Our laboratories are led by board-certified clinical neurologists and clinical chemists who have extensive experience using testing to guide patient care. These experts are available for consultations on test selection and results interpretation. Our physicians are committed to research and discovery to pave the way for the future of neurology testing.
Comprehensive disease testing
A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories, including:
The latest
Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.
Mayo Clinic Laboratories and Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States. The test (test ID ASYNC) is available today for clients of Mayo Clinic Laboratories through the collaboration that combines the expertise of both organizations to enhance patient care and improve diagnostic accuracy for neurodegenerative diseases.
Mayo Clinic Laboratories is thrilled to participate in the American Academy of Neurology (AAN) Annual Meeting, which will be held in San Diego on April 5–9, 2025. Our lab and clinical experts are leading an evolution in neurology diagnostics and are committed to staying at the forefront of discovery.
The fifth episode of “Life of a Specimen” video series highlights Joy Carol’s treatment journey after Mayo Clinic Laboratories antibody testing identified a paraneoplastic autoimmune disorder as the cause of her life-threatening symptoms.
After years of misdiagnosis, Tyler Hart found answers at Mayo Clinic, discovering he had NF155-IgG4 autoimmune nodopathy instead of CIDP
The fourth episode of “Life of a Specimen” video series explores the diagnosis enabled by antibody testing on Joy Carol’s cerebrospinal cord fluid and how her test result illuminated a path forward.
The third episode of “Life of a Specimen” video series discusses the integration that drives the development of innovative tests, including the movement disorders evaluation, at Mayo Clinic Laboratories.
Check out the second episode of “Life of a Specimen,” a video exploration of the complex path taken by patient samples through testing at Mayo Clinic Laboratories. In this episode, we hear about the quality processes and careful treatment given to each sample received for testing.
Check out the first episode of “Life of a Specimen,” a video series that examines the critical journey taken by patient samples through Mayo Clinic Laboratories testing. In this video, we learn about the profound impact of our testing on one extraordinary patient.
An order-entry, clinical decision support tool developed by physicians and scientists at Froedtert and the Medical College of Wisconsin (MCW) for clinicians within the healthcare system who order autoimmune and paraneoplastic antibody panels has significantly improved test utilization, resulting in a 28% reduction in monthly test volumes of impacted tests.
Performed on cerebrospinal fluid, Mayo Clinic’s RT-QuIC prion test can distinguish prion disease from other types of rapidly progressive dementias to enhance patient care.
Presentation Recording Coming Soon PACE / State of FLThis webinar will discuss the advantages of using electrophysiology results to guide the selection of axonal or demyelinating testing for peripheral neuropathy. This approach can help identify specific antibodies associated with the condition, providing a more precise diagnosis, and improving patient outcomes. Accurate diagnosis is crucial for effective treatment, as the therapeutic approach varies based on the underlying cause of peripheral neuropathy.
This microlearning will help learners develop the ability to include autoimmune movement disorders and related phenomena as part of the differential diagnosis, gain proficiency in categorizing autoimmune movement disorders based on phenotype and clinical progression, and identify effective strategies for diagnosing and managing autoimmune movement disorders.